AIPLA tells US Congress: We cannot support Innovation Act

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

AIPLA tells US Congress: We cannot support Innovation Act

AIPLA has written to Congress saying it cannot support the Innovation Act because of objections to several provisions within the bill and the speed with which the legislation has moved forward.

The association, which represents about 15,000 lawyers and other IP professionals, urged Congress to “take a balanced approach that also continues to encourage innovation” when considering the bill, otherwise known as H.R. 3309.

In the letter, sent yesterday, AIPLA made suggestions including:


· Ensure that Section 3 and Section 6 do not “interfere with the traditional discretion of the courts by avoiding inflexible legislatively mandated rules.” Section 3 would require more transparency in claims and oblige patent holders making claims not “reasonably justified in law and fact” to pay the other party’s attorneys fees.

· Retain Section 9(c), which would require the USPTO to use the same claim construction standard in inter partes and post-grant review as is used by district courts. At present, the USPTO uses the “broadest reasonable interpretation” standard, which is designed to prevent overly broad claims and is less advantageous to patent holders than the standard used by the district courts.

· Rewrite Section 5, which allows courts to stay suits against customers when there is parallel litigation against a manufacturer, so that is “not so overbroad that genuine infringers receive the protection intended for the innocent.”

· Remove Section 9(a), which strikes Section 145 of the AIA. Section 145 allows patent applicants to challenge the USPTO’s refusal of a patent application in district court after appealing to the USPTO’s Patent Trial and Appeal Board (PTAB). (Other potential recourses for applicants include appealing directly to the Federal Circuit under Section 141 or filing a continuation application.)

· Retain Section 9(b), which would strike “or could reasonably have raised” from the estoppel provisions of 35 USC Section 325. AIPLA claims this would encourage those challenging patents to do so in the early stages of the patent term, “when reliance, commercialisation and related investment are likely at their minimum.”

· Give further consideration to other provisions, such as Section 9(d) on double patenting, Section 9(f) on patent term adjustment, and Section 9(g) on clarification of jurisdiction.

AIPLA also said it was disappointed the bill did not “secure full funding” for the USPTO. The organisation has been campaigning to have the USPTO exempted from budget sequestration.

more from across site and SHARED ros bottom lb

More from across our site

Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gift this article